Maxim Group set a $2.00 price objective on Cytori Therapeutics (NASDAQ:CYTX) in a research report released on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other analysts have also weighed in on CYTX. Zacks Investment Research lowered Cytori Therapeutics from a hold rating to a sell rating in a report on Thursday, March 8th. Laidlaw restated a buy rating and set a $1.65 price target on shares of Cytori Therapeutics in a report on Thursday, February 22nd. Finally, ValuEngine upgraded Cytori Therapeutics from a strong sell rating to a sell rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $1.80.
Shares of Cytori Therapeutics (NASDAQ:CYTX) opened at $0.32 on Friday. Cytori Therapeutics has a twelve month low of $0.22 and a twelve month high of $2.08. The stock has a market capitalization of $11.41, a P/E ratio of -0.37 and a beta of 3.49.
In other Cytori Therapeutics news, major shareholder Ag Postfinance sold 286,982 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $0.31, for a total value of $88,964.42. Following the transaction, the insider now owns 5,118,627 shares of the company’s stock, valued at approximately $1,586,774.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total value of $38,000.00. Following the completion of the transaction, the insider now directly owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The disclosure for this sale can be found here. Insiders have sold a total of 695,767 shares of company stock worth $231,951 in the last 90 days. 1.90% of the stock is currently owned by insiders.
An institutional investor recently raised its position in Cytori Therapeutics stock. Perkins Capital Management Inc. raised its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 134.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,136,041 shares of the biotechnology company’s stock after acquiring an additional 1,223,046 shares during the quarter. Perkins Capital Management Inc. owned approximately 6.08% of Cytori Therapeutics worth $644,000 as of its most recent filing with the Securities & Exchange Commission. 10.57% of the stock is currently owned by institutional investors and hedge funds.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.